Overall survival with momelotinib vs. best available therapy in patients with ruxolitinib-experienced myelofibrosis: a matching-adjusted indirect comparison.

ABSTRACT:

SUBMITTER: Palandri F 

PROVIDER: S-EPMC12924849 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature